ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/05/2025 07:29 PDT] ACAD, Expected to Trade Lower After Bearish Insider Trading
• [04/11/2025 07:28 PDT] ACAD Expected to Trade Up After Bullish Patterns Develop
• [04/09/2025 07:18 PDT] ACAD Expected to Trade Down After Bearish Patterns Develop
• [04/04/2025 14:17 PDT] ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Down By 100% ($16.61) From $16.61 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [04/01/2025 07:37 PDT] ACAD Expected to Trade Down Short Term
• [03/27/2025 07:52 PDT] ACAD, Expected to Trade Lower After Bearish Insider Trading
• [03/26/2025 07:14 PDT] ACAD Expected to Trade Up After Bullish Patterns Develop
• [03/24/2025 07:03 PDT] ACAD Expected to Trade Down Short Term
• [03/20/2025 07:03 PDT] ACAD Expected to Trade Up After Bullish Patterns Develop
• [03/13/2025 07:14 PDT] ACAD Expected to Trade Down Short Term
• [03/12/2025 07:08 PDT] ACAD Expected to Trade Down After Bearish Patterns Develop